Revvity (RVTY)
NYSE:RVTY
Top Page
Revvity
(NYSE:RVTY)
Select Model
Select Model
Rating:64Neutral
Price Target:
$93.00
▲(5.87% Upside)
Action:ReiteratedDate:02/03/26
The score is primarily driven by solid financial performance led by strong free-cash-flow generation and improved leverage, tempered by weaker profitability versus prior years. Technicals are constructive longer term but show near-term consolidation. Valuation is the biggest constraint due to the high P/E and low yield, while the latest earnings call supports a moderately positive view with steady EPS/FCF outlook but only modest growth and near-term margin pressure.
Positive Factors
Free Cash Flow Strength
Consistent, high FCF conversion ($515M in 2025, Q4 $162M, ~85–87% conversion) provides durable internal funding for R&D, M&A and shareholder returns. Strong cash generation supports deleveraging and capital allocation flexibility even if top-line growth remains modest.
Negative Factors
Modest Organic Growth Outlook
Management's 2–3% organic growth guide indicates limited top‑line momentum. With life‑sciences instrumentation and some end markets soft, structural revenue expansion will be slow, constraining operating leverage and the pace at which margins and returns can re‑accelerate.
Read all positive and negative factors
Positive Factors
Negative Factors
Free Cash Flow Strength
Consistent, high FCF conversion ($515M in 2025, Q4 $162M, ~85–87% conversion) provides durable internal funding for R&D, M&A and shareholder returns. Strong cash generation supports deleveraging and capital allocation flexibility even if top-line growth remains modest.
Read all positive factors
Revvity (RVTY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$9.82B
Dividend Yield0.29%
Average Volume (3M)1.17M
Price to Earnings (P/E)27.9
Beta (1Y)0.91
Revenue Growth3.37%
EPS Growth-18.80%
CountryUS
Employees11,000
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)1.70
Shares Outstanding111,803,330
10 Day Avg. Volume1,128,087
30 Day Avg. Volume1,168,328
Financial Highlights & Ratios
PEG Ratio-3.32
Price to Book (P/B)1.52
Price to Sales (P/S)3.85
P/FCF Ratio21.63
Enterprise Value/Market Cap1.26
Enterprise Value/Revenue4.33
Enterprise Value/Gross Profit8.64
Enterprise Value/Ebitda16.16
Forecast
1Y Price Target
$112.36Price Target Upside27.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)5.4
Revenue Forecast (FY)$2.98B
Revvity Business Overview & Revenue Model
Company Description
Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solu...
How the Company Makes Money
Revvity generates revenue primarily by selling (1) instruments and related hardware platforms, (2) recurring consumables and reagents that run on those platforms, (3) software/informatics products, and (4) services such as maintenance, support, an...
Revvity Earnings Call Summary
Earnings Call Date:Feb 02, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 04, 2026
Earnings Call Sentiment Neutral
The call highlighted clear operational resilience—EPS and cash flow beats, strong diagnostics and software momentum, major share repurchases, and strategic AI/software initiatives—offset by persistent end-market softness, China diagnostic weakness, margin pressure and a conservative 2026 growth outlook. Achievements (guidance beat, FCF strength, software traction, ACD acquisition, Signals Synthetica launch) are balanced by notable challenges (modest organic growth guidance, China DRG impacts, near-term margin headwinds, rising below-the-line costs), resulting in a cautious but constructive tone.Positive Updates
Quarterly and Full-Year Revenue Performance
Q4 revenue of $772 million with 4% organic growth; full-year revenue of $2.86 billion with 3% organic growth, in line with prior guidance despite headwinds.
Negative Updates
Modest Overall Growth and Conservative Outlook
Company reiterated a cautious 2026 organic growth outlook of 2%–3%, signaling only modest near-term demand improvement after a 3% organic growth year.
Read all updates
Q4-2025 Updates
Positive
Negative
Quarterly and Full-Year Revenue Performance
Q4 revenue of $772 million with 4% organic growth; full-year revenue of $2.86 billion with 3% organic growth, in line with prior guidance despite headwinds.
Read all positive updates
Company Guidance
Revvity guided 2026 with 2–3% organic growth (Q1 in line with the full‑year), an approximate 1% FX tailwind for the year (≈3% FX benefit in Q1), and ~75 bps contribution (~$20M) from the ACD acquisition, implying total revenue of $2.96–$2.99 billion; adjusted operating margin is targeted at 28% (cost‑efficiency programs to be completed by end of Q2, with margins stepping up in Q2 and the back half after a Q1 trough of ~23%), and full‑year adjusted EPS is guided to $5.35–$5.45 (high‑single‑digit EPS growth) with Q1 EPS expected to be ~19% of the full year. Management assumes diluted shares of ~112 million, adjusted net interest & other of ~$95M (up from $84M), an 18% adjusted tax rate (vs. 14.5% in 2025), and expects free‑cash‑flow conversion of ~85%+ (2025 conversion was 87% with $515M FCF; Q4 FCF was $162M). The extra operating week in Q1 provides ~100 bps of organic‑growth tailwind (~20 bps FY) but is roughly a $0.06 EPS headwind.Revvity Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
70
Positive
Cash Flow
78
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.86B | 2.76B | 2.75B | 3.31B | 3.83B |
| Gross Profit | 1.52B | 1.32B | 1.32B | 1.76B | 2.28B |
| EBITDA | 662.72M | 840.25M | 713.56M | 1.18B | 1.62B |
| Net Income | 241.68M | 295.83M | -118.38M | 569.18M | 943.16M |
Balance Sheet | |||||
| Total Assets | 12.17B | 12.39B | 13.56B | 14.13B | 15.00B |
| Cash, Cash Equivalents and Short-Term Investments | 919.87M | 1.16B | 1.60B | 454.36M | 603.32M |
| Total Debt | 3.52B | 3.33B | 4.07B | 4.60B | 5.16B |
| Total Liabilities | 4.92B | 4.73B | 5.69B | 6.75B | 7.86B |
| Stockholders Equity | 7.25B | 7.67B | 7.87B | 7.38B | 7.14B |
Cash Flow | |||||
| Free Cash Flow | 508.25M | 541.65M | 9.90M | 594.18M | 1.32B |
| Operating Cash Flow | 581.78M | 628.30M | 91.27M | 679.81M | 1.41B |
| Investing Cash Flow | -17.35M | 776.16M | 1.31B | -132.85M | -4.11B |
| Financing Cash Flow | -855.05M | -1.13B | -947.12M | -661.80M | 2.94B |
Revvity Technical Analysis
Negative
87.84
Price Trends
99.58
Negative
98.70
Negative
95.36
Negative
Market Momentum
-3.48
Negative
39.73
Neutral
61.89
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RVTY, the sentiment is Negative. The current price of 87.84 is below the 20-day moving average (MA) of 90.53, below the 50-day MA of 99.58, and below the 200-day MA of 95.36, indicating a bearish trend. The MACD of -3.48 indicates Negative momentum. The RSI at 39.73 is Neutral, neither overbought nor oversold. The STOCH value of 61.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RVTY.
Revvity Risk Analysis
Revvity disclosed 24 risk factors in its most recent earnings report. Revvity reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Revvity Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $8.40B | 23.17 | 11.85% | 3.31% | 5.32% | 336.29% | |
70 Neutral | $21.58B | 19.42 | 13.88% | 1.80% | 13.74% | 14.87% | |
64 Neutral | $9.82B | 27.94 | 3.24% | 0.29% | 3.37% | -18.80% | |
62 Neutral | $20.03B | -92.15 | -8.51% | ― | 14.47% | -353.69% | |
59 Neutral | $19.30B | 24.21 | 34.94% | ― | -2.39% | ― | |
54 Neutral | $11.36B | -30.76 | 164.85% | ― | 30.38% | 24.17% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
RVTY
Revvity
87.84
-19.22
-17.95%
EXAS
Exact Sciences
104.91
59.99
133.55%
ILMN
Illumina
126.20
43.37
52.36%
QGEN
Qiagen
40.63
1.19
3.02%
DGX
Quest Diagnostics
196.46
32.88
20.10%
GH
Guardant Health
86.58
40.74
88.87%
Revvity Corporate Events
Business Operations and StrategyFinancial Disclosures
Revvity Raises 2025 Outlook With Strong Preliminary Results
Positive
Jan 13, 2026
On January 12, 2026, Revvity said it will report its fourth-quarter and full-year 2025 results before the market opens on February 2, 2026, followed by an earnings call led by CEO Prahlad Singh and CFO Max Krakowiak, and confirmed that Singh is sc...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.